About tisotumab vedotin-tftv
Class: | Antibody-drug conjugate (ADC)
Use: | Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy
Adult dose: | 1.25 mg/kg administered intravenously every 3 weeks (up to a maximum of 200 mg per dose)
Pediatric dose: | Safety and efficacy have not been established in pediatric patients; not recommended for use in this population
Side effects: | Fatigue, nausea, diarrhea, alopecia, peripheral neuropathy, and infusi
Drug Class
Antibody-drug conjugate (ADC)
Uses & Indications
Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy
Storage Requirements
Store refrigerated at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light
Manufacturer & Packaging
Manufacturer: SEAGEN INC., United States of America
Package Size
VIAL
Price & Supplier
Price in UAE: AED 36225.00
Dosage Information
Adult Dose
1.25 mg/kg administered intravenously every 3 weeks (up to a maximum of 200 mg per dose)
Pediatric Dose
Safety and efficacy have not been established in pediatric patients; not recommended for use in this population
Side Effects
Fatigue, nausea, diarrhea, alopecia, peripheral neuropathy, and infusion-related reactions
Contraindications & Precautions
Hypersensitivity to tisotumab vedotin-tftv or any component of the formulation; pregnancy (due to potential fetal harm)
Important Warnings
Risk of ocular toxicity (including severe eye disorders), infusion-related reactions, and peripheral neuropathy; monitor patients closely for these effects
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.